Company-reported prevalence
Tirabrutinib
Overview
| Field | Value |
|---|---|
| Drug | Tirabrutinib |
| Indication | Primary central nervous system lymphoma |
| Disease | Primary central nervous system lymphoma (PCNSL), including relapsed or refractory PCNSL |
| Company | Ono Pharmaceutical Co., Ltd. (developer; worldwide rights); Deciphera Pharmaceuticals, a member of Ono Pharmaceutical (United States development and commercialization since July 2025); ONO Pharma USA (United States affiliate, functions integrated into Deciphera in July 2025) |
| Documents searched | Deciphera Pharmaceuticals pipeline page (accessed October 2026); Deciphera Pharmaceuticals news index (accessed October 2026); Navigating PCNSL disease awareness website, home, What is R/R PCNSL, Current treatment challenges, Future outlook, and Resources pages (May 2026); PROSPECT study recruitment website (accessed October 2026); ONO Pharma USA home, pipeline, and clinical trials pages (accessed October 2026); press releases of February 2026, May 2025, March 2024, March 2023, July 2021, March 2020, and December 2019; Ono Pharmaceutical integrated report 2026; Ono Pharmaceutical financial results presentations and transcripts of May 2026 and July 2026; Ono Pharmaceutical R&D Day presentation and transcript of June 2026; Ono Pharmaceutical R&D briefing transcript on the PROSPECT study (2025); Ono Pharmaceutical J.P. Morgan Healthcare Conference presentation, January 2026 |
| Data as of | October 14, 2026 |
| Prepared by | AI research agent (Claude); not yet reviewed by a person |
Company statements of prevalence
United States
Incidence: Deciphera Pharmaceuticals press release, February 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Incidence: Ono Pharmaceutical corporate presentation, January 2026
“The incidence rate is approx. 5 cases per million” (opens the source at this quote in a new tab)
“per year in the US” (opens the source at this quote in a new tab)
Cited source: None stated in the document.
(opens the full-size image in a new tab)Incidence: Ono Pharmaceutical press release, March 2024
Cited source: 2.1 Ostrom 2022
(opens the full-size image in a new tab)Incidence: Deciphera Pharmaceuticals disease awareness website, May 2026
Cited source: 2.4 Yamanaka 2017
(opens the full-size image in a new tab)Number diagnosed: Deciphera Pharmaceuticals disease awareness website, May 2026
“In the US” (opens the source at this quote in a new tab)
“~1,900 people were diagnosed with PCNSL in 2023” (opens the source at this quote in a new tab)
Cited source: 2.4 Yamanaka 2017
(opens the full-size image in a new tab)Incidence: ONO Pharma USA press release, July 2021
Cited source: None stated in the document.
(opens the full-size image in a new tab)Europe
No evidence found.
Global
No evidence found.
Other countries and regions
Incidence (Japan): Ono Pharmaceutical corporate presentation, January 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Incidence: Ono Pharmaceutical press release, March 2020
Geography not stated
Prevalence (share of patients refractory to initial treatment or relapsing): Deciphera Pharmaceuticals press release, February 2026
Cited source: None stated in the document.
(opens the full-size image in a new tab)Prevalence (share of patients refractory to first-line treatment or relapsing): Deciphera Pharmaceuticals disease awareness website, May 2026
Sources the company cites
Ostrom 2022
Reference as the company lists it
Passage carrying the figure
Brain tumor registry of Japan 2017
Reference as the company lists it
Passage carrying the figure
Not quoted: The cited document is the Brain Tumor Registry of Japan report for 2005 to 2008, a 94-page set of tables of hospital-registered case counts; its text states no annual number of new cases in Japan, and the figure of 980 does not appear in it.
Japanese journal of neurosurgery 2015
Reference as the company lists it
Passage carrying the figure
Not quoted: The reference names a journal issue (volume 24, number 10, October 2015) without an article title, author, or page; the issue holds several articles, and no single cited document could be identified.
Yamanaka 2017
Passage carrying the figure
Not quoted: Closed access. The abstract reports outcomes of 112 participants with PCNSL diagnosed between 1982 and 2006 in Japan and states no incidence rate or number of diagnoses for the United States.
National comprehensive cancer network 2026
Reference as the company lists it
Passage carrying the figure
Not quoted: The guideline is available only to registered users of the National Comprehensive Cancer Network website.
References
- Brain Tumor Registry of Japan 2017 (opens in a new tab)
- Deciphera Pharmaceuticals (2026) Navigating PCNSL website, What is R/R PCNSL page (opens in a new tab)
- Deciphera Pharmaceuticals (2026) press release, February 17, 2026 (opens in a new tab)
- National Comprehensive Cancer Network (2026) Central Nervous System Cancers guideline (opens in a new tab)
- ONO Pharma USA (2021) press release, July 19, 2021 (opens in a new tab)
- Ono Pharmaceutical (2020) press release, March 25, 2020 (opens in a new tab)
- Ono Pharmaceutical (2024) press release, March 21, 2024 (opens in a new tab)
- Ono Pharmaceutical (2026) corporate presentation, J.P. Morgan Healthcare Conference, January 2026 (opens in a new tab)
- Ostrom 2022 (opens in a new tab)
- Yamanaka 2017 (opens in a new tab)